linjc16/ctgov huggingface dataset:
L-Arginine in Children Having Sickle Cell Disease With Increased Tricuspid Regurgitant Jet Velocity

Study Overview
=================
Brief Summary
-----------------
This study aims to investigate the possible efficacy and safety of L-Arginine in children having Sickle Cell Disease with increased Tricuspid Regurgitant Jet Velocity

Official Title
-----------------
Clinical Study to Evaluate the Possible Efficacy and Safety of L-Arginine in Children Having Sickle Cell Disease With Increased Tricuspid Regurgitant Jet Velocity

Conditions
-----------------
Sickle Cell Disease

Intervention / Treatment
-----------------
* Drug: L-Arginine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: children having Sickle Cell Disease with increased Tricuspid Regurgitant Jet Velocity age 5-18 years Exclusion Criteria: Another chronic hemolytic anemia. Patients with documented causes of pulmonary hypertension other than SCD. Allergy to L-arginine. Patients with Asthma. Hepatic dysfunction: serum Alanine Aminotransferase (ALT) > 3X upper value. Renal dysfunction: Creatinine level greater than or equal to 1.2 mg/dl.

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: control group<br>this group will include 25 patients who will receive their standard therapy for 3 months | |
| Active Comparator: L-Arginine group<br>this group will include 25 patients who will receive L-Arginine 0.1-0.2 g/kg/day and their standard therapy for 3 months | Drug: L-Arginine<br>* L-Arginine 1000 mg free form, rapid release capsules<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in tricuspid regurgitant jet velocity (TRJV) detected by Color Doppler Echocardiography | patients will undergo Color Doppler Echocardiography to assess tricuspid regurgitant jet velocity (TRJV) at baseline and after 3 months | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in serum level of N-terminal pro b-type natriuretic peptide (NT-pro-BNP) | Blood samples will be collected at baseline and after 3 months | 3 months | 
| change in serum level of L-Arginine | Blood samples will be collected at baseline and after 3 months | 3 months | 
| change in serum level of Asymmetric Dimethyl Arginine (ADMA) | Blood samples will be collected at baseline and after 3 months | 3 months | 
| change in serum level of Nitric Oxide | Blood samples will be collected at baseline and after 3 months | 3 months |
Effectiveness of Prophylactic Bolus Ephedrine Versus Norepinephrine for Management of Post Spinal Hypotension

Study Overview
=================
Brief Summary
-----------------
This study was conducted to compare the effectiveness of ephedrine versus norepinephrine for management of hypotension after spinal anesthesia for mothers undergoing elective cesarean section

Official Title
-----------------
Effectiveness of Prophylactic Bolus Ephedrine Versus Norepinephrine for Management of Post Spinal Hypotension During Elective Caesarean Section in Resource Limited Setting: a Prospective Cohort Study

Conditions
-----------------
Comparing Ephedrine With Norepinephrine for Mangement Postspinal Hypotension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA class II and ages ranging from 18-35 years were included in the study Exclusion Criteria: pregnant women with preeclampsia/eclampsia, baseline hypertension (SBP> 140 mm Hg), BMI> 30 kg/m2, failed spinal, spinal anaesthesia converted to general anaesthesia, contraindication for spinal anaesthesia and mother with cardiovascular, renal or hepatic disease.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to compare mean blood pressure (MAP) between the groups |  | From March,01 to April, 30/2022 |
Methylphenidate Treatment Response Study of Genetic Polymorphism in Attention Deficit Hyperactivity Disorder(ADHD)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether norepinephrine gene polymorphism affect to treatment response in ADHD

Official Title
-----------------
Functional Brain Markers and Predictors of Treatment Response Associated With Norepinephrine System Genes in ADHD

Conditions
-----------------
Attention Deficit Hyperactivity Disorder

Intervention / Treatment
-----------------
* Drug: Methylphenidate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis made by DSM-IV and K-SADS-PL IQ > 71 Exclusion Criteria: genetic disorder history of acquired brain injury seizure disorder other neurologic disorder mental disorder, pervasive developmental disorder obsessive-Compulsive disorder communication disorder learning disorder

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Methylphenidate<br> | Drug: Methylphenidate<br>* mg/kg dose: 0.7 1.2mg/kg PO daily morning intake 8 weeks<br>* Other names: Penid;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical Global Impression Scale-Improvement |  | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ADHD rating scale |  | 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Attention Deficit Hyperactivity Disorder, Polymorphism, Single Nucleotide, SLC6A2 protein, human, ADRA2A protein, human
Glucometer and Mobile-phone Based Data Transfer System in Diabetes

Study Overview
=================
Brief Summary
-----------------
To determine if glucometer combined with mobile-phone based data transfer system would be useful for patient diabetes to manage their glycemic control.

Detailed Description
-----------------
Patients with diabetes who are advised by their providers to self-monitoring of blood glucose are eligible. Patients who decline or are not able to do self-monitoring of blood glucose will serve as controls.

Official Title
-----------------
Efficacy of Combination of Glucometer and Mobile-phone Based Data Transfer System on Glycemic Control in Patients With Diabetes

Conditions
-----------------
Diabetes

Intervention / Treatment
-----------------
* Device: Breeze2 glucometer
* Device: Breeze2 glucometer and H2


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with diabetes Patients' providers advised self-monitor of blood glucose Provided written informed consent. Exclusion Criteria: 1. Patients had other medical condition that were considered not eligible by the medical team members

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control<br>patients who decline or unable to do self-monitoring of blood glucose | |
| Active Comparator: Breeze2 glucometer<br>patients who do self-monitoring of blood glucose, but do not transfer data via mobile-phone | Device: Breeze2 glucometer<br>* Breeze2 glucometer for self-monitoring of blood glucose<br>|
| Experimental: Breeze2 glucometer and H2<br>patients who do self-monitoring of blood glucose and transfer data via mobile-phone | Device: Breeze2 glucometer<br>* Breeze2 glucometer for self-monitoring of blood glucose<br>Device: Breeze2 glucometer and H2<br>* Breeze2 glucometer and Health2Sync Mobile App for data transfer<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HbA1c |  | HbA1c change from baseline at month 3 and 6 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hypoglycemia | Hypoglycemia was defined as a glucose value less than 70 mg/dl, or with typical symptoms of hypoglycemia. The information of hypoglycemia will be collected at each site visit (every 1-2 month). | event of hypoglycemia at month 3 and 6 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diabetes, glucometer, mobile-phone
Assessing Impacts of Static Magnetic Fields on Peripheral Pulses and Skin Blood Flow

Study Overview
=================
Brief Summary
-----------------
The purpose of this research study is to investigate and determine the effects of static magnetic fields produced by a small magnet on peripheral pulses and skin blood flow.

Detailed Description
-----------------
A specific neodymium magnet and sham device will be placed on certain sites near the ulnar and medial arteries and the effect of such placement on peripheral pulses assessed via PPG on fingers and on skin blood flow via laser Doppler perfusion determined. These assessments will be made while healthy subjects are lying supine on a padded examination table over a time interval of about 45-60 minutes. In addition to the impact that either the magnet or the sham devices have, the pulse and skin blood flow patterns and features will be analyzed from the point of view of sequential variability with and eye toward developing related parameters to potentially improve such variability.

Official Title
-----------------
Assessing Impacts of Static Magnetic Fields on Peripheral Pulses and Skin Blood Flow

Conditions
-----------------
Arterial Stiffness, Magnetic Field Exposure, Peripheral Arterial Disease

Intervention / Treatment
-----------------
* Device: magnet and sham


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 18-35 years No known neurological deficit No known cardiovascular condition Exclusion Criteria: Unable or unwilling to lie reasonably still for about 55 minutes Known to have diabetes of any type Having any metallic or wire implant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Healthy Adults-magnet<br>Healthy adults with magnet and/or sham | Device: magnet and sham<br>* In same subject some areas will have magnet and others will have sham<br>|
| Sham Comparator: Healthy Adults-sham<br>Healthy adults with magnet and/or sham | Device: magnet and sham<br>* In same subject some areas will have magnet and others will have sham<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect of magnet on skin blood flow | skin blood flow | one hour | 
| Effect of magnet on arterial pulses | Pulse values and paterns | one hour | 
| Characterization of temporal pattern of pulse changes and their amelioration | variability with and without normalization | one hour |
PST Linkage Based Analysis in the Family of More Than Two Members With Type 1 Diabetes in Taiwan

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to explore the susceptible genes for Type 1 diabetes in Taiwan through the new genetic study methods.

Detailed Description
-----------------
As an unclear autoimmune disorder, the pathogenesis of type 1 diabetes (T1D) remains elusive. Among all the methods for studying diseases pathophysiology, genetic approach has valuable capability as being both hypothesis-testing and hypothesis-generating. Although geo-epidemiological studies show relatively higher prevalence of T1D in Caucasians than in Asians, whether genetic factors identified in T1D of Caucasians are essential for T1D in Asians is not yet clarified. Although the human leukocyte antigen (HLA) genotype variants have been reported to be associated with T1D, the odds ratio (ORs) is relatively low in Taiwan as comparing with western countries, some families are indeed more than one child with T1D. However, the genetic linkage study in T1D is still limited in Taiwan that hampered the drug development or research in T1D. Therefore, we intend to explore the susceptible genes for T1D of Taiwan in this study, which will provide further researcher directions for this disease.

Official Title
-----------------
Parent-sibling Tracing (PST) Linkage Based Analysis in the Family of More Than Two Members With Type 1 Diabetes in Taiwan for Novel HLA and Non-HLA Candidate Risk Alleles Detection

Conditions
-----------------
The Genetic Variation of Type 1 Diabetes

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 1 diabetes on the criteria of the American Diabetes Association with a very low C-peptide level (<0.35 ng/mL) with or without the experience of diabetic ketoacidosis. The subjects whose four grandparents are of Chinese Han origin Exclusion Criteria: Patients with ages of onset more than 35 years are excluded. The families having any member with known possible type 2 diabetes
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Type 1 DM<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Type 1 diabetes gene |  | 1 year |
Assessment of Spinal Stability

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to verify the existence of neuromuscular neutral zones(NNZs) in humans, and develop non-invasive techniques to measure intervertebral kinematics of the lumbar spine. The results will be used to accurately quantify NNZs in humans, and provide a foundation for clinical trials on low back pain patients using this methodology.

Official Title
-----------------
Neuromuscular Neutral Zones in Humans: A New Method to Assess Spinal Stability

Conditions
-----------------
Spine Stability, Low Back Pain

Intervention / Treatment
-----------------
* Procedure: method (non-surgical) to measure neuromuscular neutral zones


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 21-45 years of age - typical working age in physically demanding jobs no history of low back injury or musculoskeletal disorder in the past one year any activity history: sedentary, active, or non-athletic, and 4) any ethnic background or race body mass index score less than 30 Exclusion Criteria: Younger than 21 or older than 45 years old (range not relevant to majority of physical labor force) previous injury, disorder, or illness related to the low back professional athletes professional workers engaged in physical labor (e.g., roofers, loaders/unloaders in warehouses, tile/concrete layers, etc.) pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| healthy<br>Healthy and active men and women between 21 and 45 years old with no history of low back pain or low back injury. | Procedure: method (non-surgical) to measure neuromuscular neutral zones<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| neuromuscular neutral zones |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lumbar spine, low back pain
Netrin-1 & Hepatocellular Carcinoma HCC

Study Overview
=================
Brief Summary
-----------------
Netrin-1 is a dependence receptor ligand participating in the pathology of several cancer types. It is up-regulated in chronic liver diseases, cirrhosis and HCC. We hypothesize that netrin-1 may play a detrimental role in HCC. The goal of this project is to characterize netrin-1 signals in HCC samples with ad hoc controls, to investigate the benefit of capturing netrin-1 in preclinical models of HCC and to try to define patients groups the most likely to benefit from this targeting approach in the clinic.

Official Title
-----------------
Netrin-1 in Hepatocellular Carcinoma: Pathology, Preclinical Targeting, and Definition of Eligibility Criteria for Phase 1 Trials

Conditions
-----------------
HCC

Intervention / Treatment
-----------------
* Procedure: Quantification of netrin-1 signals by antibody-based approaches


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: any patient suffering from HCC age >18 informed consent provided Exclusion Criteria: - absence of informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Tumors (T) samples of various etiologies (HBV, HCV, NASH, alcool)<br>The combination of the Tumors status of the sample combined with its etiology ((HBV, HCV, NASH, alcool) | Procedure: Quantification of netrin-1 signals by antibody-based approaches<br>* Samples have been obtained upon curative surgery without any other therapy administered and subsequently characterized by pathologists after FFPE inclusion.<br>|
| Non Tumors (NT) samples of various etiologies (HBV, HCV, NASH, alcool)<br>The combination of the Non Tumors status of the sample combined with its etiology ((HBV, HCV, NASH, alcool) | Procedure: Quantification of netrin-1 signals by antibody-based approaches<br>* Samples have been obtained upon curative surgery without any other therapy administered and subsequently characterized by pathologists after FFPE inclusion.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Netrin-1 expression patterns in HCC samples | Netrin-1 expression levels will be quantified by immunoblotting with ad hoc internal standards. Positivity threshold by IHC will be evaluated using ad hoc positive and negative control tissues. The densitometry approach will be used. | Outcome measure is to be performed after surgery of the tumors (at least 1 year later). It has no impact on the patient's care. |
Evaluation of an Internal Hospital Practice: The Effect of Altered Test Tubes Sampling Order on Blood Culture Contamination Rates

Study Overview
=================
Brief Summary
-----------------
Implementation of the initial specimen diversion technique, in which the first milliliter of the venipuncture sample is not injected into the culture bottle, led to a significant reduction in blood culture contamination rates. This technique is based on the assumption that the skin plug aspirated during venipuncture is a major source of contaminating bacteria. One such diversion method is aspirating the first blood volume into a blood collection tube. It has, however, been suggested that regular blood collection tubes carry contaminants from the tube's stopper into the blood cultures drawn afterwards, thereby increasing contamination rates. The aim of this trial is to examine the effect of aspirating the first blood volume into a regular blood collection tube on blood culture contamination rate.

Official Title
-----------------
Evaluation of an Internal Hospital Practice: The Effect of Altered Sampling Protocol on Blood Culture Contamination Rates: An Open, Randomized, Prospective Study

Conditions
-----------------
Septicemia

Intervention / Treatment
-----------------
* Diagnostic Test: aspirating first blood volume into a regular blood collection tube


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults evaluated in the emergency room or as inpatients for suspected sepsis or having sepsis and from whom the treating physician plans to take, in the same venous puncture, blood cultures and additional blood tests (blood count and/or blood chemistry). Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Initial Specimen Diversion<br>Aspirating first blood volume into a regular blood collection tube | Diagnostic Test: aspirating first blood volume into a regular blood collection tube<br>* order of blood drawing<br>|
| Active Comparator: Standard practice<br>Aspirating first blood into blood culture bottles (Standard practice) | Diagnostic Test: aspirating first blood volume into a regular blood collection tube<br>* order of blood drawing<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood culture contamination rate | A blood culture contamination is defined as growth in a single set of coagulase-negative Staphylococcus, Micrococcus, Viridans group Streptococcus, Propionibacterium acne, Corynebacterium sp (diphtheroids) or Bacillus sp. | 7 days |